GlaxoSmithKline/Human Genome Sciences

Target: Human Genome Sciences
Buyer: GlaxoSmithKline ($GSK)
Price: $3 billion
Closed: Aug. 3, 2012

The hardest fought negotiations of the year, at least publicly, came in GlaxoSmithKline's $3 billion takeover of partner Human Genome Sciences. HGS felt GSK launched its attack at a weak moment for the company, getting it on the cheap. But after months of saying no, and then hell no, it had to face the facts. No one else was coming to the rescue.

The buyout gave GSK full rights to lupus treatment Benlysta. The drug has yet to live up to expectations but could still break out for some big sales numbers. In addition, GSK and HGS have been collaborating on the diabetes drug albiglutide as well as the promising late-stage heart drug darapladib. GSK also expects to wring out about $200 million in annual costs by 2015 by consolidating the two operations.

GlaxoSmithKline/Human Genome Sciences

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.